🇺🇸 IFN-alpha in United States
38 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 38
Most-reported reactions
- Gene Mutation — 5 reports (13.16%)
- Abdominal Pain — 4 reports (10.53%)
- Arthralgia — 4 reports (10.53%)
- Fatigue — 4 reports (10.53%)
- Maternal Exposure During Pregnancy — 4 reports (10.53%)
- Nausea — 4 reports (10.53%)
- Rash — 4 reports (10.53%)
- Arteriosclerosis — 3 reports (7.89%)
- Asthenia — 3 reports (7.89%)
- Atrial Fibrillation — 3 reports (7.89%)
Other Oncology approved in United States
Frequently asked questions
Is IFN-alpha approved in United States?
IFN-alpha does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for IFN-alpha in United States?
Active Biotech AB is the originator. The local marketing authorisation holder may differ — check the official source linked above.